CYTOKINETICS INC 4

EVP Research & Development Fady Ibraham Malik exercised options for 3,500 Cytokinetics (CYTK) shares at $7.80 and sold 3,500 shares at $75.82 on 2026-08-18.

On August 18, 2026, Dr. Fady Ibraham Malik, EVP Research & Development of Cytokinetics, Inc., exercised a non-qualified stock option to acquire 3,500 shares of common stock at an exercise price of $7.80 per share and, on the same day, sold 3,500 shares of common stock at a price of $75.82 per share. The option exercise added 3,500 shares to his direct holdings at a cost basis implied by the $7.80 strike, while the open-market sale at $75.82 generated gross proceeds of approximately $265,370. Following these transactions, Dr. Malik directly owned 153,902 shares of Cytokinetics common stock. The option exercised appears to have been granted on March 27, 2018 and is scheduled to expire on February 27, 2028. These paired exercise-and-sell transactions are characteristic of routine liquidity or tax-management events rather than a net accumulation of shares.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000088

Alert Tier

6